Back HIV/AIDS

HIV / AIDS

Updated U.S. Guidelines for Antiretroviral Treatment of Children with HIV

The U.S. Department of Health and Human Services has updated its Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Reflecting recent data from the START and PENPACT1 trials, the guidelines now recommend that all children with HIV start antiretroviral therapy (ART) regardless of CD4 T-cell count, viral load, or clinical symptoms.

alt

CROI 2016: Transgender People at High Risk for HIV, But Little Is Known About Prevention and Treatment

Transgender women have among the highest rates of HIV infection, but little is known about HIV prevalence among trans men, Tonia Poteat from Johns Hopkins Bloomberg School of Public Health said in a plenary lecture on transgender health and HIV at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016)in Boston -- the first ever on this population at CROI. A growing number of studies and prevention and treatment programs are addressing transgender populations, but more research is needed.

alt

CROI 2016: High Levels of Chemsex and Slamsex Seen Among HIV+ Men at U.K. HIV Clinics

A survey of HIV-positive clients attending 30 HIV clinics in England and Wales, presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston, has found that nearly a third (29%) of gay male patients reported engaging in "chemsex" (defined by the researchers as "the use of drugs to increase disinhibition and arousal") in the past year and that 1 in 10 reported "slamsex" (injecting or being injected with such drugs). Figures were higher for some subgroups: 37% of Londoners reported chemsex and nearly 1 in 5 (19%) of men on antiretroviral therapy (ART) reported slamsex.

alt

CROI 2016: HIV-Related Factors Increase Risk of Stroke

HIV-related risk factors seem to increase the risk of stroke -- the sudden death of brain cells due to a rupture or obstruction of blood vessels in the brain -- according to ongoing research in a growing number of large epidemiological cohort studies. Recent data from 5 of these were presented during the first-ever poster discussion session on stroke at the Conference on Retroviruses and Opportunistic Infections (CROI), which took place last month in Boston.

alt

FDA Approves Second TAF-Containing Single-Tablet HIV Regimen

The U.S. Food and Drug Administration (FDA) this week approved Gilead Sciences' new once-daily single-tablet regimen Odefsey, containing the NNRTI rilpivirine (developed by Janssen), emtricitabine, and tenofovir alafenamide or TAF, a new formulation that is easier on the kidneys and bones than the older tenofovir disoproxil fumarate or TDF.

alt

CROI 2016: START Study Shows People Starting HIV Treatment Earlier Have Better Quality of Life

Rather than treatment side effects having a negative impact on people’s quality of life when they start HIV treatment, data from the large randomized START study show a modest but statistically significant improvement in quality of life, according to a presentation at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.

alt

CROI 2016: Maraviroc May Work as PrEP in a Combination, but Probably Not Alone

Two studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last week in Boston outlined the first findings from the NEXT-PrEP study, otherwise known as HPTN 069. What NEXT-PrEP has discovered so far indicates that the drug maraviroc (Selzentry) could have a role in pre-exposure prophylaxis, or PrEP, when used alongside either tenofovir or emtricitabine (the component drugs in Truvada), but is not potent enough to act as PrEP by itself.

alt